Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine

Parabolus Medicines made headlines with a $770.5 million IPO, the largest ever for a drug developer, sending its stock 58% higher on debut before settling above the $20 offering price. The Cambridge‑based firm leverages its Helicon platform to create stabilized helical peptides that inhibit the notoriously undruggable beta‑catenin‑TCF interaction. With roughly $150 million earmarked for desmoid tumor trials and another $120 million for hepatocellular carcinoma and other indications, the capital raise underscores investor appetite for novel peptide therapeutics and highlights the growing market for antibody‑drug conjugates.

Big pharma’s AI appetite is crystallizing in multi‑hundred‑million collaborations, exemplified by Merck’s partnership with Protillion Biosciences. The deal promises up to $510 million in milestone payments for AI‑driven antibody discovery using Protillion’s ProtMap chip platform, which can evaluate a million protein variants in 48 hours. This follows Merck’s recent $2.2 billion alliance with Quotient Therapeutics and an $838 million pact with Infinimmune, reflecting a strategic shift toward external tech expertise to accelerate pipeline replenishment as blockbuster patents expire. While the financial commitments are clear, the industry still seeks concrete data on time‑to‑market reductions and cost efficiencies.

On the clinical front, a first‑in‑human trial of a dual Lassa‑Rabies vaccine (Lassa‑RAB) demonstrated safety and robust antibody responses against both pathogens in 54 healthy volunteers, offering a freeze‑dryable formulation suited for low‑resource settings. Simultaneously, researchers at Jennifer Doudna’s lab engineered a CRISPR‑Cas12A2 system that recognizes mutant p53 mRNA and triggers chromatin shredding, eradicating cancer cells in mouse models of lung and liver tumors. These advances illustrate how cutting‑edge biotech—from peptide therapeutics to AI‑enhanced discovery and genome editing—are converging to address unmet medical needs, though their ultimate impact will hinge on successful clinical translation and scalable manufacturing.